Slowing growth, stubborn inflation drive a broad-based decline in shares.

In-line sales for Alzheimer’s drug Leqembi and a beat for rare-disease drug Skyclarys has Wall Street giving Biogen another chance.

The Tokyo Stock Exchange aims to attract listings from Asian startups, leveraging the market’s recent gains and positioning itself as a preferred fundraising destination for companies outside Japan.

A new study suggests people are overly optimistic about how much they can work later in life.

The Facebook parent’s capital expenditures this year will rival outlays from Google and Microsoft, but advertising growth is slowing.

The price of the metal has surged and BHP has bid for miner Anglo American, but the bull case for the metal is a bit more complicated than it seems.